Beatriz Manzor Mitrzyk, Melissa A Plegue, Reema Kadri, Shivang U Danak, Joseph D Hubbard, Emily A Kaip, Dana N Roberson, Souvik Roy, Timothy C Guetterman, Vicki L Ellingrod, Karen B Farris, Mack T Ruffin Iv, Michael S Klinkman, Lorraine R Buis
{"title":"精神健康药物基因组测试(第二部分):早期采用者处方感知的定性分析。","authors":"Beatriz Manzor Mitrzyk, Melissa A Plegue, Reema Kadri, Shivang U Danak, Joseph D Hubbard, Emily A Kaip, Dana N Roberson, Souvik Roy, Timothy C Guetterman, Vicki L Ellingrod, Karen B Farris, Mack T Ruffin Iv, Michael S Klinkman, Lorraine R Buis","doi":"10.2217/pme-2020-0084","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> We sought to explore how early adopters use pharmacogenomic (PGx) testing for treating depression and attention-deficit/hyperactivity disorder. <b>Patients & methods:</b> Prescribers of the <i>Informed PGx</i> (Progenity, Inc., Ann Arbor, MI 48108, USA) test completed a phone survey assessing use of PGx testing for different scenarios. We conducted a qualitative thematic text analysis of transcribed audio recordings of open-ended responses (n = 62). <b>Results:</b> PGx testing was used when treating multiple comorbidities or resistant disease, and to ease patients' concerns with future therapy. Use of PGx testing is influenced by insurance coverage, interpretability of results and results turnaround time. <b>Conclusion:</b> Prescribers used PGx tests to modify medications for complex patients with depression, attention-deficit/hyperactivity disorder and other disorders to alleviate concerns related to adverse effects and lack of effectiveness.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 3","pages":"233-240"},"PeriodicalIF":1.7000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Pharmacogenomic testing for mental health (Part II): qualitative analysis of early adopter prescriber perceptions.\",\"authors\":\"Beatriz Manzor Mitrzyk, Melissa A Plegue, Reema Kadri, Shivang U Danak, Joseph D Hubbard, Emily A Kaip, Dana N Roberson, Souvik Roy, Timothy C Guetterman, Vicki L Ellingrod, Karen B Farris, Mack T Ruffin Iv, Michael S Klinkman, Lorraine R Buis\",\"doi\":\"10.2217/pme-2020-0084\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> We sought to explore how early adopters use pharmacogenomic (PGx) testing for treating depression and attention-deficit/hyperactivity disorder. <b>Patients & methods:</b> Prescribers of the <i>Informed PGx</i> (Progenity, Inc., Ann Arbor, MI 48108, USA) test completed a phone survey assessing use of PGx testing for different scenarios. We conducted a qualitative thematic text analysis of transcribed audio recordings of open-ended responses (n = 62). <b>Results:</b> PGx testing was used when treating multiple comorbidities or resistant disease, and to ease patients' concerns with future therapy. Use of PGx testing is influenced by insurance coverage, interpretability of results and results turnaround time. <b>Conclusion:</b> Prescribers used PGx tests to modify medications for complex patients with depression, attention-deficit/hyperactivity disorder and other disorders to alleviate concerns related to adverse effects and lack of effectiveness.</p>\",\"PeriodicalId\":19753,\"journal\":{\"name\":\"Personalized medicine\",\"volume\":\"18 3\",\"pages\":\"233-240\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Personalized medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pme-2020-0084\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/3/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2020-0084","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1
摘要
目的:我们试图探索早期采用者如何使用药物基因组学(PGx)测试来治疗抑郁症和注意力缺陷/多动障碍。患者和方法:知情PGx (Progenity, Inc, Ann Arbor, MI 48108, USA)测试的处方者完成了一项电话调查,评估PGx测试在不同情况下的使用情况。我们对开放式回答的转录录音进行了定性专题文本分析(n = 62)。结果:PGx检测用于治疗多种合并症或耐药疾病,并缓解患者对未来治疗的担忧。PGx测试的使用受到保险覆盖、结果的可解释性和结果周转时间的影响。结论:处方医师使用PGx测试来修改抑郁症、注意力缺陷/多动障碍和其他疾病复杂患者的药物,以减轻与不良反应和缺乏有效性相关的担忧。
Pharmacogenomic testing for mental health (Part II): qualitative analysis of early adopter prescriber perceptions.
Aim: We sought to explore how early adopters use pharmacogenomic (PGx) testing for treating depression and attention-deficit/hyperactivity disorder. Patients & methods: Prescribers of the Informed PGx (Progenity, Inc., Ann Arbor, MI 48108, USA) test completed a phone survey assessing use of PGx testing for different scenarios. We conducted a qualitative thematic text analysis of transcribed audio recordings of open-ended responses (n = 62). Results: PGx testing was used when treating multiple comorbidities or resistant disease, and to ease patients' concerns with future therapy. Use of PGx testing is influenced by insurance coverage, interpretability of results and results turnaround time. Conclusion: Prescribers used PGx tests to modify medications for complex patients with depression, attention-deficit/hyperactivity disorder and other disorders to alleviate concerns related to adverse effects and lack of effectiveness.
期刊介绍:
Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis.
The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.